• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Temporal Trends in Ischemic Stroke and Anticoagulation Therapy for Nonvalvular Atrial Fibrillation: Impact of Diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention. This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes - February 29, 2016 Category: Endocrinology Authors: Gautam R. SHROFF, Craig A. SOLID, Zachary BLOOMGARDEN, Jonathan L. HALPERIN, Charles A. HERZOG Tags: Original Article Source Type: research

Temporal trends in ischemic stroke and anticoagulation therapy for non‐valvular atrial fibrillation: effect of diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention.
Source: Journal of Diabetes - April 12, 2016 Category: Endocrinology Authors: Gautam R. Shroff, Craig A. Solid, Zachary Bloomgarden, Jonathan L. Halperin, Charles A. Herzog Tags: Original Article Source Type: research

Temporal trends in ischemic stroke and anticoagulation therapy for non ‐valvular atrial fibrillation: effect of diabetes
ConclusionsIschemic stroke declined and warfarin use increased similarly in Medicare patients with and without diabetes. Ischemic stroke rates were consistently higher in diabetes patients, validating the inclusion of diabetes in risk calculators. The population of Medicare patients with diabetes who did not receive warfarin deserves future attention.
Source: Journal of Diabetes - April 12, 2016 Category: Endocrinology Authors: Gautam R. Shroff, Craig A. Solid, Zachary Bloomgarden, Jonathan L. Halperin, Charles A. Herzog Tags: Original Article Source Type: research

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of medicare part d beneficiaries.
CONCLUSIONS: Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use. PMID: 23324508 [PubMed - in process]
Source: The Annals of Pharmacotherapy - January 1, 2013 Category: Drugs & Pharmacology Authors: Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS Tags: Ann Pharmacother Source Type: research

National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries
Source: Annals of Pharmacotherapy Area: Evidence > Medicines Management > References Background: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low.  In 2008, the US Medicare Part D programme was expanded to pay for medications for Medicare enrollees. Objective: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. Methods: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in ...
Source: NeLM - Cardiovascular Medicine - January 24, 2013 Category: Cardiology Source Type: news

Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study
ConclusionAdherence to oral anticoagulants is suboptimal. Interventions tailored according to past adherence trajectories may be effective in improving patient ’s adherence.
Source: International Journal of Clinical Pharmacy - July 1, 2022 Category: Drugs & Pharmacology Source Type: research